AN2 Therapeutics, Inc.
ANTX
16 insider filings · Latest: May 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Jun 2 4:31 PM | Sarah Joanne WilliamsPrincipal Accounting Officer | Sale | 265 | $4.43 | $1.2K | 66,583(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | Mar 23 7:02 PM | Robin Shane ReadnourDirector | Grant/Award | 44,466 | — | 23,742(D) | View → |
| Mar 19, 2026 | Mar 23 7:02 PM | Robin Shane ReadnourDirector | Disposition | 44,466 | $17.28 | 0(D) | View → |
| Mar 19, 2026 | Mar 23 7:00 PM | Easom EricDirector, Chief Executive Officer | Grant/Award | 742,649 | — | 267,650(D) | View → |
| Mar 19, 2026 | Mar 23 7:00 PM | Easom EricDirector, Chief Executive Officer | Disposition | 742,649 | $17.28 | 0(D) | View → |
← Previous
Page 2 of 2